Abivax SA

Abivax is a clinical-stage biotechnology company committed  to advancing treatments in inflammation and immunology by harnessing the power of microRNA biology.  Abivax is currently evaluating our lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis (“UC”), as well as evaluating other potential inflammatory indications. We focus on indications where existing treatments have left patients with significant unmet needs, and where we believe our investigational agents have the potential to be meaningfully differentiated from currently available therapies. For more information, visit www.Abivax.com.